Forendo Pharma, a clinical stage drug development company focusing on novel treatments in women’s health, today announces that it has raised an additional €4 million of funding from Vesalius Biocapital III Partners (Vesalius III). This is in addition to the €12 million Series A financing in 2014 and €5,7 million R&D loans granted by Business Finland since 2014. Vesalius III joins the existing international investor syndicate comprising Novo Seeds, Karolinska Development, Novartis Venture Fund, M Ventures and Innovestor. Stéphane Verdood, Managing Partner from Vesalius III, joins Forendo Pharma’s Board of Directors.